Catalent to Invest $9 Million to Establish San Diego Clinical Supply Facility
The new facility will handle clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction and will include stability chambers.
Catalent announced on Sept. 5, 2019 that it will invest $9 million into a new clinical supply facility in San Diego, CA. The facility will begin operations in the summer of 2020.
The new facility will provide clinical supply services to pharmaceutical and biopharmaceutical customers and will specialize in services for early-phase clinical trials while enhancing the company’s OptiForm Total Supply service, which offers customers integrated development, clinical supply manufacturing, and distribution. The facility will also handle clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction and will include stability chambers.
“This investment supports Catalent’s commitment to offering customers greater flexibility and expanded support for early-phase studies,” said Paul Hegwood, president, clinical supply services, in a company press release. “The facility will allow Catalent to provide superior clinical services throughout the western corridor of the [Unites States] and Canada’s drug development region.”
The facility will join two existing Catalent global centers of excellence in oral dose early-phase development in Somerset, NJ, and Nottingham, UK.
Source: Catalent
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
